As U.S. Pharmaceutical Companies Look to Continue Improving Patient Health, Over 40 Brands Select Dendrite to Enhance Patient Adherence

Dendrite International, Inc., (NASDAQ: DRTE) a leading provider ofpharmaceutical industry solutions, has been quickly growing its U.S.adherence programs, with 42 distinct pharmaceutical brands adoptingthis service, and more than 12 million loyalty cards in patients'hands during the past 12 months. The growing adoption of theseprograms reflects the industry's embrace of strategies that fosterpatient adherence to therapy prescribed by doctors to help achievebetter patient health outcomes. Dendrite has had a growing presence asan innovator of these strategic programs.

Dendrite's proprietary adherence programs are designed tointegrate the patient, prescriber, pharmacy and managed careorganization. Multi-channel interventions are deployed by Dendrite inthese initiatives, including one of the industry's leading adjudicatedcard programs with access to approximately 97 percent of the majorretail pharmacies nationwide, ensuring maximum ease of use for engagedpatients.

The uptake of Dendrite's adherence programs comes at a time whenrecent industry estimates indicate that between 15-25 percent of totalprescriptions remain unfilled, while approximately 30-40 percent ofpatients never refill a prescription in spite of doctors' orders --all potentially causing a serious impact on patient health, whileplacing a significant strain on the healthcare system.

"Our proprietary adherence programs are built on the foundation ofrelationship marketing and enable an interactive, completelycustomized dialog between the brand and its customers," said RickRose, vice president and general manager for Dendrite MarketingSolutions. "Our adherence programs make it easy for brands to delivercomprehensive adherence solutions that integrate all customerconstituencies. Today, increasing numbers of our clients arecentralizing cross-brand adherence efforts within Dendrite MarketingSolutions because of our superior pharmacy reach and because ourproprietary approach and campaign management platform enables rapid,scalable, and cost-efficient implementation."

About Dendrite

Founded in 1986, Dendrite International (NASDAQ: DRTE) enablessales, marketing, clinical and compliance solutions for the global,pharmaceutical industry. The Company's clients are located in morethan 50 countries and include the world's top 20 pharmaceuticalcompanies. For more information, please visit www.dendrite.com.

Note: Dendrite is a registered trademark of DendriteInternational, Inc.

This document may contain forward-looking statements that may beidentified by such forward-looking terminology as "expect," "believe,""anticipate," "will," "intend," "plan," "target," "outlook,""guidance," and similar statements or variations. Such forward-lookingstatements are based on our current expectations, estimates,assumptions and projections and involve significant risks anduncertainties, including risks which may result from our dependence onthe pharmaceutical industry; fluctuations in quarterly revenues due tolengthy sales and implementation cycles for certain of our solutions;our fixed expenses in relation to fluctuating revenues and variationsin customers' budget cycles; dependence on certain major customers;changes in demand for our products and services attributable to anyweakness experienced in the economy or mergers, acquisitions andconsolidations in the pharmaceutical industry; successful and timelydevelopment and introduction of new products and versions; rapidtechnological changes; increased competition; internationaloperations; integrating the entities we acquire; our ability toeffectively manage our growth; the protection of our proprietarytechnology; our ability to compete in the Internet-related productsand services market; the continued demand for Internet-relatedproducts and services; the ability of our third party vendors torespond to technological change; our ability to maintain ourrelationships with third-party vendors; less favorable thananticipated results from strategic relationships; dependence of datasolutions on strategic relationships; events which may affect the U.S.and world economies; and catastrophic events which could negativelyaffect our information technology infrastructure. Other importantfactors that should be reviewed and carefully considered are includedin the company's 10-K, 10-Qs, and other reports filed with the SEC.Actual results may differ materially. The company assumes noobligation for updating any such forward-looking statements to reflectactual results, changes in assumptions or other changes affecting suchforward-looking statements.